The status and advances of radiofrequency catheter ablation for atrial fibrillation

doi:10.3969/j.issn.1004-583X.2016.01.005

Abstract

Abstract: Atrial fibrillation is one of the most common arrhythmias in clinic. The biggest risk of atrial fibrillation is thromboembolism, the most common complication is stroke. With the aging of population, more and more people suffer from atrial fibrillation, so the treatment of atrial fibrillation has gradually become the focus problem. Radiofrequency catheter ablation for atrial fibrillation is one of the important treatment methods, it can obviously improve the prognosis of patients with atrial fibrillation. And with the development of technology, ablation method has been mature, the status of radiofrequency catheter ablation for atrial fibrillation is gradually improved. However, there is no fixed operation method up to now. The mechanism of atrial fibrillation is not thoroughly explicit, especially for persistent atrial fibrillation. There are still some problems with radiofrequency catheter ablation for atrial fibrillation to further investigate.

Key words: atrial fibrillation, radiofrequency catheter ablation

CLC Number:

R541.75

Xie Ruiqin, Yin Guangli, Yang Yingtao. The status and advances of radiofrequency catheter ablation for atrial fibrillation[J]. Clinical Focus, 2016, 31(1): 19-21.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.005

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/19

References

[1] Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med,1998,339(10): 659-666.
[2] Saad EB, Rossillo A, Saad CP, et al. Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy[J]. Circulation,2003,108(25): 3102-3107.
[3] Pappone C, Manguso F, Vicedomini G, et al. Prevention of iatrogenic atrial tachycardia after ablation of atrial fibrillation: a prospective randomized study comparing circumferential pulmonary vein ablation with a modified approach[J].Circulation,2004,110(19): 3036-3042.
[4] Dong JZ, Sang CH, Yu RH, et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation[J]. Europace,2015,May 8.[Epub ahead of print].
[5] Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation[J]. Circulation,2005,111(9):1100-1105.
[6] Ren JF, Marchlinski FE, Callans DJ, et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast[J]. J Cardiovasc Electrophysiol,2005,16(5):474-477.
[7] Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study[J]. J Am Coll Cardiol,2003,42(2):185-197.
[8] Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial[J]. JAMA,2014,311(7): 692-700.
[9] Raatikainen MJ, Hakalahti A, Uusimaa P, et al. Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial[J]. Int J Cardiol,2015,198:108-114.
[10] Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation[J]. N Engl J Med,2006,354(9): 934-941.
[11] 苏春芳,靳维华.心房颤动最新抗凝治疗进展[J].心血管病学进展,2012,33(3):142-146.
[12] 郝振.老年阵发性房颤的治疗进展[J].吉林医学,2011,32(22):121-123.
[13] Lim KT, Matsuo S, O'Neill MD, et al. Catheter ablation of persistent and permanent atrial fibrillation: Bordeaux experience[J]. Expert Rev Cardiovasc Ther,2007,5(4): 655-662.

[1]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[2]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[3]	Zhang Fang, Zhang Yichao, Jia Xinwei, Li Jianlong, Chen Chunhong. Analysis of one-year follow-up results of ≥75-year-old atrial fibrillation inpatients with high CHA2DS2-VASc score [J]. Clinical Focus, 2023, 38(2): 117-120.
[4]	Ma Jinghong, Yang Qian, Jia Yongjian, Dang Yi. Risks of cardiac tamponade resulting from uninterrupted novel oral anticoagulants and uninterrupted warfarin during perioperative period of catheter ablation of atrial fibrillation: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 773-778.
[5]	Zhang Haifu, Ye Xiangqing, Chen Zhexu, Chen Shijian, Yang Dong, Zhang Xingwei. Effects of moderate exercise on the prognosis of patients with atrial fibrillation:A systematic review and Meta-analysis [J]. Clinical Focus, 2022, 37(6): 485-489.
[6]	Zhang Jingshui, Xu Yanan, Wang Jun, Yang Yi, Jiang Haibing, Tang Long, Wang Xianping, Shao Mingliang. Clinical characteristics and long-term prognosis of initial patients with new onset different type of heart failure combined atrial fibrillation [J]. Clinical Focus, 2022, 37(6): 504-509.
[7]	Li Weiwei, Li Yanan. Left atrial volume index predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis [J]. Clinical Focus, 2022, 37(11): 965-968.
[8]	An Jingjing, Wang Xiaojuan, Deng Aiyun. Radiofrequency ablation in treating pre-excited atrial fibrillation recurrence: A meta analysis [J]. Clinical Focus, 2022, 37(10): 899-904.
[9]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[10]	Geng Yanping, Wang Lili, Gu Jian, Qi Peng, Chen Shuxia. Validity and reliability analysis of Chinese version of AntiClot Treatment Scale [J]. Clinical Focus, 2020, 35(9): 788-791.
[11]	Ma Jincai, Ma Rongzhi, Ma Zhenzhen. Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency [J]. Clinical Focus, 2020, 35(5): 413-416.
[12]	Yang Hua, Meng Limin, Xin Shuanli, Chang Chao, Zhao Xiufeng, Wang Min. Correlation between serum chemerin levels and degree of atrial fibrosis in patients with atrial fibrillation [J]. Clinical Focus, 2020, 35(3): 206-210.
[13]	Lu Yuqin, Li Yingdong, Liu Kai. Role of serum MMP-1, MMP-3, TIMP-1 and Hcy levels in patients with hypertension complicated with atrial fibrillation [J]. Clinical Focus, 2020, 35(11): 976-979.
[14]	Gao Xiuxina, Si Yueqiaoa, Ding Zhenjianga, Zhang Yinga, Liu Huilinga, Liu Jingyia, Han Chaoa, Sunwang Lexianaa. Correlation of platelet distribution width and red blood cell distribution width in peripheral blood with atrial fibrillation in patients with coronary artery disease [J]. Clinical Focus, 2020, 35(11): 984-987.
[15]	Nuozha Dainier, Muhuyati. Metaanalysis of factors influencing recurrence after radiofrequency ablation of atrial fibrillation [J]. Clinical Focus, 2019, 34(3): 267-272.